A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression
Latest Information Update: 14 Jun 2025
At a glance
- Drugs Psilocybin (Primary)
- Indications Depression
- Focus Registrational; Therapeutic Use
- Acronyms COMP 006
- Sponsors COMPASS Pathways
Most Recent Events
- 09 May 2025 Planned End Date changed from 1 May 2025 to 1 Dec 2026.
- 09 May 2025 Planned primary completion date changed from 1 Mar 2025 to 1 Feb 2026.
- 10 Jan 2025 According to a COMPASS Pathways media release, the company announced the pricing of an offering. The company intends to use the net proceeds from this offering to fund this study.